Extracellular Vesicle/Exosome Upstream Process Development: Maximizing Productivity to Accelerate… April 01, 2022 Biomanufacturing, EVs & Exosomes
Maintaining CQAs as Manufacturing Processes are Scaled from 2D to 3D Bioreactor Culture February 28, 2022 Biomanufacturing, Quality & Regulatory
“One Does Not Simply Walk Into” a Therapeutic Cell Manufacturing Process… But the Long Road… November 03, 2021 BioEconomy, Biomanufacturing, Bioprocess Tools, Cell Therapy
hUC-MSCs Are Unique: Are the Biomaterials, Bioprocesses, & Clinical Product Developers Now “in… July 27, 2021 Cell Therapy, MSCs & Characterization
Identify & Define Your Cell Therapy’s Biomanufacturing Approach for Critical Process… April 27, 2021 Biomanufacturing, Quality & Regulatory
Critical Quality Attributes (CQAs): Know Their Importance & Limitations in Product & Process… April 27, 2021 Biomanufacturing, Quality & Regulatory
“Known Unknowns” Affect Critical Process Parameters & Critical Quality Attributes in the… April 22, 2021 Biomanufacturing, Quality & Regulatory
Building Effective Multi-Year Process Development Programs II: Evolution of Technology Platform Decisions… March 30, 2021 BioEconomy, Biomanufacturing, Bioprocess Tools, Cell Therapy
Building Effective Multi-Year Process Development Programs I: Estimating hMSC Lot Size Ranges for… March 16, 2021 BioEconomy, Biomanufacturing, Bioprocess Tools, Cell Therapy
